| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Departments of Medicine and Molecular Pharmacology, and the Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York
Whereas the major folate transporter, the reduced folate carrier (RFC), has a physiological pH optimum, transport activities for folates and antifolates have been detected with low pH optima. Because the interstitial pH in solid tumors is generally acidic, the mechanisms by which antifolates are transported at low pH could be an important determinant of drug activity under these conditions. The current study quantitated the low pH methotrexate (MTX) transport activity in human solid tumor cell lines from the National Cancer Institute tumor panel and other sources. MTX influx at pH 5.5 was equal to, or greater than, influx at pH 7.4 in 29 of 32 cell lines. To assess the role of RFC in transport at low pH in one of these cell lines, a HeLa clonal line (R5) was selected for MTX resistance due to a genomic deletion of the carrier gene. MTX influx was depressed by 70% in R5 versus wild-type HeLa cells at pH 7.4. At pH 6.5, influx in these two lines was similar; as the pH was decreased to 5.5 influx increased in both cell lines. Similarly, whereas net MTX uptake over 1 h was markedly decreased in R5 cells at pH 7.4, net uptake in HeLa and R5 cells was comparable at pH 6.5. Also, as compared with MCF7 breast cancer cells, MTX uptake was markedly decreased at pH 7.4, but only minimally at pH 6.5, in the MDA-MB-231 human breast cancer cell line that lacks RFC expression. When grown with folic acid (2 µM) at pH 7.4, the IC50 for MTX was 14-fold higher in R5 as compared with wild-type HeLa cells; the difference was only 4-fold when cells when grown at pH 6.9; the IC50s were identical at this pH when the medium folate was 25 nM 5-formyltetrahydrofolate. These data demonstrate that transport activity at low pH is prevalent in human solid tumors, is RFC-independent in R5 cells and MDA-MB-231 breast cancer cells, and can preserve MTX activity in the absence of RFC at an acidic pH relevant to solid tumors in vivo.
This article has been cited by other articles:
|
|
 |
|
  A. Qiu, S. H. Min, M. Jansen, U. Malhotra, E. Tsai, D. C. Cabelof, L. H. Matherly, R. Zhao, M. H. Akabas, and I. D. Goldman Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1669 - C1678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nakai, K. Inoue, N. Abe, M. Hatakeyama, K.-y. Ohta, M. Otagiri, Y. Hayashi, and H. Yuasa Functional Characterization of Human Proton-Coupled Folate Transporter/Heme Carrier Protein 1 Heterologously Expressed in Mammalian Cells as a Folate Transporter J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 469 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chattopadhyay, R. Tamari, S. H. Min, R. Zhao, E. Tsai, and I. D. Goldman Commentary: A Case for Minimizing Folate Supplementation in Clinical Regimens with Pemetrexed Based on the Marked Sensitivity of the Drug to Folate Availability Oncologist, July 1, 2007; 12(7): 808 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chattopadhyay, R. G. Moran, and I. D. Goldman Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications Mol. Cancer Ther., February 1, 2007; 6(2): 404 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Breedveld, D. Pluim, G. Cipriani, F. Dahlhaus, M. A. J. van Eijndhoven, C. J. F. de Wolf, A. Kuil, J. H. Beijnen, G. L. Scheffer, G. Jansen, et al. The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models Mol. Pharmacol., January 1, 2007; 71(1): 240 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kaufman, I. Ifergan, L. Rothem, G. Jansen, and Y. G. Assaraf Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss Blood, April 15, 2006; 107(8): 3288 - 3294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chattopadhyay, R. Zhao, S. A. Krupenko, N. Krupenko, and I. D. Goldman The inverse relationship between reduced folate carrier function and Pemetrexed activity in a human colon cancer cell line. Mol. Cancer Ther., February 1, 2006; 5(2): 438 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Liu, Y. Ge, D. C. Cabelof, A. Aboukameel, A. R. Heydari, R. Mohammad, and L. H. Matherly Structure and Regulation of the Murine Reduced Folate Carrier Gene: IDENTIFICATION OF FOUR NONCODING EXONS AND PROMOTERS AND REGULATION BY DIETARY FOLATES J. Biol. Chem., February 18, 2005; 280(7): 5588 - 5597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zhao, S. Zhang, M. Hanscom, S. Chattopadhyay, and I. D. Goldman Loss of Reduced Folate Carrier Function and Folate Depletion Result in Enhanced Pemetrexed Inhibition of Purine Synthesis Clin. Cancer Res., February 1, 2005; 11(3): 1294 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, A. Rajgopal, I. D. Goldman, and R. Zhao Preservation of folate transport activity with a low-pH optimum in rat IEC-6 intestinal epithelial cell lines that lack reduced folate carrier function Am J Physiol Cell Physiol, January 1, 2005; 288(1): C65 - C71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zhao, S. Chattopadhyay, M. Hanscom, and I. D. Goldman Antifolate Resistance in a HeLa Cell Line Associated With Impaired Transport Independent of the Reduced Folate Carrier Clin. Cancer Res., December 15, 2004; 10(24): 8735 - 8742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chattopadhyay, Y. Wang, R. Zhao, and I. D. Goldman Lack of Impact of the Loss of Constitutive Folate Receptor {alpha} Expression, Achieved by RNA Interference, on the Activity of the New Generation Antifolate Pemetrexed in HeLa Cells Clin. Cancer Res., December 1, 2004; 10(23): 7986 - 7993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, R. Zhao, and I. D. Goldman Characterization of a Folate Transporter in HeLa Cells with a Low pH Optimum and High Affinity for Pemetrexed Distinct from the Reduced Folate Carrier Clin. Cancer Res., September 15, 2004; 10(18): 6256 - 6264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zhao and I. D. Goldman Enter Alimta(R): A New Generation Antifolate Oncologist, June 1, 2004; 9(3): 242 - 244. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zhao, M. Hanscom, S. Chattopadhyay, and I. D. Goldman Selective Preservation of Pemetrexed Pharmacological Activity in HeLa Cells Lacking the Reduced Folate Carrier: Association with the Presence of a Secondary Transport Pathway Cancer Res., May 1, 2004; 64(9): 3313 - 3319. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
